Call or Text Us For A Free Case Evaluation: 317.920.6400 | 800.525.8028 Search Site

Takeda Pharmaceuticals Accused of Hiding Dangers of Actos

October 3, 2014 Drug Injuries, Products Liability

Actos is a Type 2 diabetes drug that was approved by the FDA in 1999. The drug decreases the insulin resistance and decreases the glucose made in the liver. It also allows the body to dispose of excess blood sugar and makes the body’s cells more sensitive to insulin.

Actos lawsuits claim Takeda Pharmaceuticals, the drug’s manufacturer, and Eli Lilly, the drug’s marketer, knew about bladder cancer risks but did not warn the public. Eli Lilly partnered with Takeda Pharmaceuticals, the largest pharmaceutical company in Japan and Asia, to market the drug. After their partnership, Actos became one of the most successful diabetes drugs of all time. U.S. sales were $3.58 billion in 2010 and the sales made up 27 percent of Takeda’s revenue.

In 2011, The FDA required Takeda to update Actos’ Warnings and Precautions to include a warning that the drug may be associated with an increased risk of bladder cancer.

More than 3,500 Actos suits have been consolidated before U.S. District Judge Rebecca Doherty in Lafayette, LA. Lawyers claim Takeda executives knew in 2004 that studies found links between Actos and cancer, but failed to issue a warning until seven years later to protect billions in sales of the drug.

If you believe your injuries or medical diagnoses is the result of a prescription drug, talk to your doctor. You should also talk to a lawyer who represents individuals against pharmaceutical companies. The lawyer will be able to give you advice on the next steps you should take and talk about your rights. Contact us to learn more.

Request A Free Case Evaluation

Fill out the form below to receive a free and confidential initial consultation.

Submitting your information does not automatically create an attorney-client relationship. I agree